Key Insights

• Benitec Biopharma will host its Annual General Meeting on 6th of December

• Total pay for CEO Jerel Banks includes US$539.5k salary

• The total compensation is 33% less than the average for the industry

• Benitec Biopharma's three-year loss to shareholders was 94% while its EPS grew by 72% over the past three years

Shareholders may be wondering what CEO Jerel Banks plans to do to improve the less than great performance at Benitec Biopharma Inc. (NASDAQ:BNTC) recently. At the next AGM coming up on 6th of December, they can influence managerial decision making through voting on resolutions, including executive remuneration. Voting on executive pay could be a powerful way to influence management, as studies have shown that the right compensation incentives impact company performance. In our opinion, CEO compensation does not look excessive and we discuss why.

See our latest analysis for Benitec Biopharma

How Does Total Compensation For Jerel Banks Compare With Other Companies In The Industry?

At the time of writing, our data shows that Benitec Biopharma Inc. has a market capitalization of US$7.8m, and reported total annual CEO compensation of US$919k for the year to June 2023. We note that's an increase of 15% above last year. We note that the salary of US$539.5k makes up a sizeable portion of the total compensation received by the CEO.

In comparison with other companies in the American Biotechs industry with market capitalizations under US$200m, the reported median total CEO compensation was US$1.4m. Accordingly, Benitec Biopharma pays its CEO under the industry median.

Speaking on an industry level, nearly 23% of total compensation represents salary, while the remainder of 77% is other remuneration. Benitec Biopharma pays out 59% of remuneration in the form of a salary, significantly higher than the industry average. If salary is the major component in total compensation, it suggests that the CEO receives a higher fixed proportion of the total compensation, regardless of performance.

A Look at Benitec Biopharma Inc.'s Growth Numbers

Benitec Biopharma Inc. has seen its earnings per share (EPS) increase by 72% a year over the past three years. In the last year, its revenue is up 2.7%.

This demonstrates that the company has been improving recently and is good news for the shareholders. It's also good to see modest revenue growth, suggesting the underlying business is healthy. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.